Powder: -20°C for 3 years | In solvent: -80°C for 1 year
QN523是一种具有类药物性质的新型支架,在12个癌症细胞系中显示出强大的体外细胞毒性。QN523在胰腺癌症异种移植模型中显示出显著的体内疗效。自噬是QN523发挥作用的主要机制。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 462 | 现货 | ||
5 mg | ¥ 1,150 | 现货 | ||
10 mg | ¥ 1,820 | 现货 | ||
25 mg | ¥ 3,660 | 现货 | ||
50 mg | ¥ 5,290 | 现货 | ||
100 mg | ¥ 7,490 | 现货 | ||
500 mg | ¥ 14,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,050 | 现货 |
产品描述 | QN523 represents a novel scaffold with drug-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 shows significant in vivo efficacy in a pancreatic cancer xenograft model. Autophagy is a major mechanism of action. |
体外活性 | QN523 showed significant cytotoxicity with IC50 values ranging from 0.1 to 5.7 μM across 12 cell lines. QN523 at 0.5 μM and gemcitabine at 0.1 μM arrested MIA PaCa-2 cells in the S-phase following 24 and 48 h treatment[1]. |
体内活性 | In NOD/SCID mice of MIA PaCa-2 xenografts, QN523 at 10 mg/kg (intraperitoneal administration) shows no significant delay in tumor growth from day 1 to day 9. QN523 at 20 mg/kg from day 10 and continued until day 44 delayed growth of the MIA PaCa-2 xenograft starting from day 17. On day 44 80% inhibition of tumor growth was observed. No symptoms of gross toxicity such as weakness, weight loss or lethargy were observed in the QN523 treatment group[1]. |
分子量 | 250.26 |
分子式 | C14H10N4O |
CAS No. | 878581-60-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 16.2mg/mL (64.7mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.9958 mL | 19.9792 mL | 39.9584 mL | 99.8961 mL |
5 mM | 0.7992 mL | 3.9958 mL | 7.9917 mL | 19.9792 mL | |
10 mM | 0.3996 mL | 1.9979 mL | 3.9958 mL | 9.9896 mL | |
20 mM | 0.1998 mL | 0.999 mL | 1.9979 mL | 4.9948 mL | |
50 mM | 0.0799 mL | 0.3996 mL | 0.7992 mL | 1.9979 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
QN523 878581-60-3 Autophagy QN-523 QN523 QN 523 Inhibitor inhibitor inhibit